Emerging life sciences company focusing on deployment and delivery of psychedelics and naturally extracted therapies to treat traumatic brain injuries Wesana Health Holdings Inc. (CSE: WESA) announced having appointed Dr. Mark Wingertzahn as their new Chief Scientific Officer.
The company expanded its executive leadership positions by hiring the PhD holder who will be in charge of leading the company’s research and drug development as well as the implementation of the company’s regulatory strategy and nonclinical programs.
“Mark’s unparalleled expertise in drug and scientific development will be a critical component in driving Wesana’s clinical programs. His leadership as Chief Scientific Officer will ensure that Wesana is positioned to advance these treatments in development and more quickly meet the needs of the many people who suffering from TBI and related conditions,” said the company’s CEO Daniel Carcillo.
Dr. Mark Wingertzahn, enjoys a wide range of experience in the medical field, he is an instructor of pediatrics at New York University. He is also an associate professor of life sciences and allied health at the New York institute of technology college of Osteopathic medicine.
